2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Immunology, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5310 Outcomes of vemurafenib-based treatment in patients with hairy cell leukemia: A retrospective multicenter study

Lauren Danielle Pomerantz, MD, Daniel Gao, MD2, Kari G Rabe, MS3, Paul J. Hampel, MD4, Michael Grever, MD5, James Stewart Blachly, MD6, Seema Ali Bhat, MD7, Lindsey Elizabeth Roeker, MD8, Yucai Wang, MD, PhD9, Saad Kenderian, M.B., Ch.B.10, Talal Hilal, MD11, Mazie Tsang, MD, MAS, MS12, Timothy Call, MD13, Kerry A. Rogers, MD14, Sameer A. Parikh, MBBS15
1 Mayo Clinic Rochester, Rochester, Minnesota, United States
2 The Ohio State University, Columbus, United States
3 Mayo Clinic Rochester, Rochester, United States
4 Mayo Clinic Rochester, Rochester, Minnesota, United States
5 The Ohio State University, Columbus, United States
6 The Ohio State University, Columbus, United States
7 The Ohio State University, Columbus, United States
8 Mayo Clinic Rochester, Rochester, Minnesota, United States
9 Mayo Clinic Rochester, Rochester, Minnesota, United States
10 Mayo Clinic Rochester, Rochester, Minnesota, United States
11 Mayo Clinic Arizona, Phoenix, United States
12 Mayo Clinic Arizona, Phoenix, United States
13 Mayo Clinic Rochester, Rochester, Minnesota, United States
14 The Ohio State University, Columbus, United States
15 Mayo Clinic Rochester, Rochester, Minnesota, United States

Background: Hairy cell leukemia (HCL) is a rare indolent mature B-cell neoplasm characterized by recurrent relapses. Although purine analogs induce durable remissions, repeated treatment is associated with cumulative myelotoxicity and immunosuppression. The BRAF V600E mutation is a validated therapeutic target in HCL with prospective studies demonstrating high response rates with vemurafenib alone or in combination with anti-CD20 antibodies (CD20mAB). To address the limited real-world evidence on vemurafenib-based treatment in the United States, we assessed its effectiveness and safety at two academic centers.

Methods: We conducted a retrospective multicenter cohort study of patients with biopsy-confirmed HCL treated with at least one dose of vemurafenib between 12/14/2012 and 12/13/2024 at Mayo Clinic and The Ohio State University. All patients had either BRAF V600E expression by IHC and/or BRAF V600E mutation confirmed prior to start of vemurafenib. Baseline demographics, disease characteristics, prior therapies, and treatment details were abstracted from the electronic medical record at both institutions. Overall response rate (ORR) included complete (CR) and partial responses (PR). Overall survival (OS) and time to next treatment or death (TTNTD) were estimated using Kaplan-Meier methods. Statistical analyses were conducted in SAS 9.4 (SAS Institute, Cary, NC).

Results: Fifty-three patients were included (35 Mayo Clinic, 18 The Ohio State University). Median age at vemurafenib initiation was 65 [25-93] years; 87% were male. Patients had received a median of 1 [0-11] prior lines of HCL therapy; 16 (30%) received vemurafenib as frontline therapy. Vemurafenib was given as monotherapy in 27 (51%) patients (10/16 [63%] frontline and 17/37 [46%] in relapsed setting), combined with rituximab in 24 (45%) patients (5/16 [31%] frontline and 19/37 [51%] relapsed), and combined with obinutuzumab in 2 (4%) patients (1/16 [6%] frontline and 1/37 [3%] relapsed). The median starting dose was 480 [240-960] mg twice a day; and the median treatment duration was 3.8 months (5.5 months for vemurafenib monotherapy and 3.4 for vemurafenib + CD20mAB).

Among 16 patients treated in the frontline setting (median follow-up, 22.5 months), ORR was 73% (15 evaluable; 6 CR, 5 PR, 2 SD, and 2 PD). The median TTNTD was 16.3 months (95% CI, 8.5- not estimable, NE) for all patients, 8.8 months (95% CI 3.8-NE) for patients treated with vemurafenib monotherapy and not reached for patients treated with vemurafenib + CD20mAB. Two-year OS was 90% (95% CI 73.2-100%) for all patients, 85.7% (95% CI 63.3-100%) with vemurafenib monotherapy and 100% (95% CI 100-100%) for vemurafenib + CD20mAB.

Among the 37 patients treated in the relapsed setting (median follow-up, 37.0 months), the ORR was 83% (35 evaluable; 18 CR, 11 PR, 3 SD, and 3 PD). Median TTNTD was 22.6 months (95% CI 17.2-NE) for all patients, 18.7 months with vemurafenib monotherapy and 27.9 months for vemurafenib + CD20mAB. Two-year OS was 83.3% (95% CI 70.7-98.1%) for all patients, including 81.4% (95% CI 64.5-100%) with vemurafenib monotherapy and 84.4% (95% CI 66.2-100%) for vemurafenib + CD20mAB. Dose reductions occurred in 18 (38%) patients. The most common adverse events were rash (24.5%) and arthralgias (20.8%); 3 patients (5.7%) experienced both. No patient discontinued treatment due to toxicity.

Conclusions: In this multicenter real-world cohort, vemurafenib-based therapy demonstrated high response rates and favorable tolerability in both frontline and relapsed HCL, with no treatment discontinuations due to toxicity. Responses appeared more durable when vemurafenib was combined with an anti-CD20 monoclonal antibody than when administered as monotherapy, although comparisons were limited by the small sample size. These findings support vemurafenib-based treatment as an effective therapeutic option for patients with HCL and provide real-world data to inform treatment selection.

Lauren Danielle Pomerantz, MD: No relevant conflicts of interest to declare.